Docket #: S19-363
A method for developing intra-epithelial innate lymphoid cells (tissue-resident NK cells) for immunotherapy
Researchers in the Sunwoo Lab have developed a method to differentiate intra-epithelial innate lymphoid cells type 1 (ieILC1s) from conventional peripheral natural kills cells for immunotherapeutic purposes. ieILC1s express higher levels of tumoricidal proteins such as interferon-gamma and granzymes in tumor microenvironments than conventional natural killer cells, leading to better tumor growth control in vivo. Thus, this differentiation method provides a pathway for ieILC1s to be adoptively transferred for immunotherapeutic purposes.
Stage of Research
Applications
- Cancer immunotherapy for solid epithelial tumors
- Differentiation of ieILC1 from NK cells
Advantages
- Differentiation and expansion of ieILC1
- High levels of tumorcidial proteins expressed from ieILC1s
- ieILC1s naturally reside within epithelial microenvironments
Related Links
Patents
- Published Application: WO2021067792
- Published Application: 20230226109
Similar Technologies
-
Methods and proteins for targeting human progenitor exhausted T cells S23-114Methods and proteins for targeting human progenitor exhausted T cells
-
Combined radiotherapy and macrophage-targeted immunotherapy of cancer to elicit abscopal responses S20-053Combined radiotherapy and macrophage-targeted immunotherapy of cancer to elicit abscopal responses
-
Blocking an immune receptor signal to treat obesity and fatty liver disease S23-015Blocking an immune receptor signal to treat obesity and fatty liver disease